Thus, only 14.2% of the patients met the guideline criteria for the use of prior agents and appropriate monitoring.
Thus, patients have a similar chance of survival after the last treatment with either O or I, irrespective of prior treatment sequence or number of prior agents.
DURATION-1 [ 31] and DURATION-5 [ 29] examined the effects of these two agents on patients who were achieving suboptimal control on diet and exercise alone ± metformin, a sulfonylurea, a thiazolidinedione, or a combination of the prior agents.
Everolimus may be used after axitinib, in view of the fact that the RECORD-1 trial also enrolled patients who had received two targeted therapies, and that the number of prior agents employed was not predictive of PFS.
33 45 50 46 44 When TNFi preceded TCZ therapy, requirements for time of discontinuation were different among prior agents: for etanercept it was at least 2 weeks, while for adalimumab and infliximab at least 8 weeks.
The preliminary results from a non-randomized phase II trial that evaluated ponatinib at a dose of 45 mg/day in heavily treated GIST patients (74 % had ≥4 prior agents) the clinical benefit rate (CR, PR, or SD ≥16 weeks) was 55 % in patients with primary KIT exon 11 mutation, but responses were also observed with the 30-mg dose [ 30, 52].
Because previous studies have shown that patients who have failed to respond to only one prior biologic agent respond significantly better to a new agent than those who have failed to respond to two or more biologic agents, this may have introduced bias if the number of prior anti-TNF agents differed by drug-exposure status [ 27].
Here, we report predictive factors for abatacept retention at 12 months identified from a cohort of patients from the ACTION study who had received at least one prior biologic agent: anti-CCP positivity, failing <2 prior anti-TNF agents, and cardiovascular comorbidity at initiation were associated with higher retention.
